NCT05264623View on ClinicalTrials.gov

Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Hyperopia With or Without Astigmatism

NAActive, not recruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

November 15, 2022

Primary Completion Date

November 20, 2026

Study Completion Date

November 20, 2026

Conditions
Hyperopia
Interventions
DEVICE

TENEO 317 Model 2 excimer laser

TENEO 317 Model 2 excimer laser use for refractive surgery

Trial Locations (9)

14228

Site 102, Amherst

15213

Site 112, Pittsburgh

33912

Site 111, Fort Myers

55416

Site 104, Saint Louis Park

55420

Site 101, Bloomington

57108

Site 108, Sioux Falls

68118

Site 103, Omaha

78613

Site 106, Cedar Park

92660

Site 113, Newport Beach

All Listed Sponsors
lead

Bausch & Lomb Incorporated

INDUSTRY